In this series, “Promise or Peril: Alarming COVID-19 mRNA Vaccine Issues,” we explore how the introduction of mRNA technology lacked an adequate regulatory framework, setting the stage for serious adverse events and other concerns related to inadequate safety testing of lipid nanoparticles, spike protein, and residual DNA and lipid-related impurities, as well as truncated/modified mRNA species.
Previously: We introduced how the FDA relaxed the rules for mRNA vaccines compared to mRNA therapies. We also discussed the available data for LNP distribution throughout the body based on animal testing and the fact that human testing was not done. Finally, we discussed the lack of biodistribution data on the mRNA and its encoded spike protein contained in the COVID mRNA vaccine. …